Abstract
Conditions under which G-CSF biosimilars have been authorised for patients' treatment: conducted studies, recommendations of the European Medicines Agency, indications authorised comparatively to the reference product. In the same way are detailed the conditions of prescription and interchangeability for that type of medicines.
Cite
CITATION STYLE
APA
Kamioner, D. (2013). G-CSFs: Onco-hematologist’s point of view. In Biosimilars: A New Generation of Biologics (Vol. 9782817803364, pp. 53–60). Springer-Verlag France. https://doi.org/10.1007/978-2-8178-0336-4_5
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free